Cole Bright was living his life like any normal 10-year-old. He played sports and video games. His life was turned upside down on October 21, 2022 when he was diagnosed with osteosarcoma. What looked like a small fracture on an X-ray was actually a bone tumor. The rigor of chemotherapy began the following week. On February 2, 2023, a team of three surgeons removed the tumor in the right distal radius and reconstructed his wrist salvaging the limb. After the surgery, he endured five more months of chemotherapy. Cole’s mom, Sarah, shares, “As of July 19, 2023, Cole is in remission. While we don’t know what the future holds, we do know that a 1 in 3 survival rate isn’t good enough. We know that no new medical advances in 40 years isn’t good enough. We hope that Cole’s journey spreads awareness for osteosarcoma and with your support we can find a cure.”

The mission of The Osteosarcoma Institute (OSI) is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. To date, OSI has committed over $11.2 million to promising osteosarcoma research in the following areas:

• Clinical trials of new potential therapies that have promising preclinical rationales
• Correlative studies that evaluate how and why a potential new therapy works, or doesn’t work, in clinical trials
• Translational studies that investigates the basic biology of osteosarcoma and its metastasis and looks for clues for how to attack it